Boc Tyr D.Met OMe | 82558-39-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc Tyr D.Met OMe
• 英文别名: Boc-L-Tyr-D-Met-OMe；N-[N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl]-D-methionine, methyl ester；methyl (2R)-2-[[(2S)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-4-methylsulfanylbutanoate
• CAS: 82558-39-2
• 化学式: C₂₀H₃₀N₂O₆S
• 分子量: 426.534
• InChiKey: UJQJOPRUCVDVPM-CVEARBPZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  29
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  139
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Boc Tyr D.Met OMe 在 盐酸 、 sodium hydroxide 、 氨 、 水 、 1-羟基苯并三唑 、 溶剂黄146 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 甲醇 、 formamide 、 N,N-二甲基甲酰胺 为溶剂， 生成 Tyr D.Met Gly Phe Leu NH2
  参考文献：
  名称：

  Audigier; Mazarguil; Gout, European Journal of Medicinal Chemistry, 1980, vol. 15, # 2, p. 173 - 177

  摘要：

  DOI：
• 作为产物：
  描述：

  D-蛋氨酸甲酯盐酸盐 、 Boc tyrosine 在 1-羟基苯并三唑 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 Boc Tyr D.Met OMe
  参考文献：
  名称：

  Audigier; Mazarguil; Gout, European Journal of Medicinal Chemistry, 1980, vol. 15, # 2, p. 173 - 177

  摘要：

  DOI：

文献信息

• Sulfide, sulfinyl and sulfone dipeptide amides
  申请人：G. D. Searle & Co.

  公开号：US04757153A1

  公开（公告）日：1988-07-12

  The invention relates to novel substituted tyrosyl alanine dipeptide amides of the formula: ##STR1## and the pharmaceutically acceptable acid addition salts thereof wherein R.sup.1 is hydrogen, lower alkyl, hydroxy, lower alkoxy, --O(CH.sub.2).sub.n phenyl with the phenyl optionally substituted by halogen, --NO.sub.2, --CN, --NH.sub.2 or lower alkyl wherein n is 1 to 4; R.sup.2 and R.sup.3 represent lower alkyl, halogen, or lower alkoxy, or either one of R.sup.2 or R.sup.3 is hydrogen and the other is lower alkyl, lower alkoxy or halogen; R.sup.4, R.sup.5, R.sup.6, and R.sup.9 may be the same or different and represent hydrogen, lower alkyl, cycloalkyl having 3 to 8 carbons, unsaturated lower alkyl, or --(CH.sub.2).sub.m cycloalkyl with the cycloalkyl having 3 to 8 carbons and m is 1 to 4; R.sup.10 is hydrogen or --(CH.sub.2).sub.p phenyl or with the phenyl optionally substituted with --NH.sub.2, --OH, halogen, --NO.sub.2, or lower alkyl or --(CH.sub.2).sub.p thienyl wherein p is 1 to 4; one of R.sup.7 or R.sup.8 is --(CH.sub.2).sub.f --S(O).sub.z --(CH.sub.2).sub.q --CH.sub.3 where f is 1 to 3 and q is 0 to 3, z is 0, 1 or 2 and the other is hydrogen or lower alkyl, or R.sup.7 and R.sup.8 together with carbon w is ##STR2## where x and y are independently 1 to 3 and z is 0, or 2. V represents an asymmetric carbon that may be recemic or have the D or L configuration; W represents an asymmetric carbon when R.sup.7 and R.sup.8 are not the same that may be recemic or have the D or L configuration. The compounds of this invention are useful as analgesic and/or antihypertensive agents.

  本发明涉及一种新的取代的酪氨酸-丙氨酸二肽酰胺，其化学式为：##STR1##以及其药学上可接受的酸加成盐。其中，R.sup.1为氢、低碳基、羟基、低烷氧基、--O(CH.sub.2).sub.n苯基，其中苯基可以选择卤素、--NO.sub.2、--CN、--NH.sub.2或低碳基取代，n为1至4；R.sup.2和R.sup.3代表低碳基、卤素或低烷氧基，或者R.sup.2或R.sup.3之一为氢，另一个为低碳基、低烷氧基或卤素；R.sup.4、R.sup.5、R.sup.6和R.sup.9可以相同也可以不同，代表氢、低碳基、具有3至8个碳的环烷基、不饱和低碳基或--(CH.sub.2).sub.m环烷基，其中环烷基具有3至8个碳，m为1至4；R.sup.10为氢或--(CH.sub.2).sub.p苯基，其中苯基可以选择--NH.sub.2、--OH、卤素、--NO.sub.2或低碳基或--(CH.sub.2).sub.p噻吩基，其中p为1至4；R.sup.7或R.sup.8之一为--(CH.sub.2).sub.f --S(O).sub.z --(CH.sub.2).sub.q --CH.sub.3，其中f为1至3，q为0至3，z为0、1或2，另一个为氢或低碳基，或者R.sup.7和R.sup.8连同碳w为##STR2##其中x和y独立地为1至3，z为0或2。V代表一个手性碳，可以是外消旋的或具有D或L构型；W代表一个手性碳，当R.sup.7和R.sup.8不同时，可以是外消旋的或具有D或L构型。本发明的化合物可用作镇痛和/或降压剂。
• Peripherally acting enkephalin analogs. 2. Polar tri- and tetrapeptides
  作者：George W. Hardy、Lawrence A. Lowe、Gail Mills、Pang Yih Sang、Dean S. A. Simpkin、Rhonda L. Follenfant、Clare Shankley、Terence W. Smith

  DOI：10.1021/jm00125a028

  日期：1989.5

  The design, synthesis, and biological activity of a series of D-Arg2-enkephalin-derived tetrapeptide amides and tripeptide aralkylamides are reported. These polar analogues were designed to be excluded from the central nervous system with their action thus limited to peripheral opioid receptors. The effects of the nature of the aromatic ring, aryl ring substitution, and aralkylamine chain length on activity were investigated; in a number of cases the N-terminal amino group of Tyr1 was converted to a guanidino group to further increase hydrophilicity. The peptides were all synthesized by classical solution methodology. The opioid activity of the peptides was assessed in vitro on the guinea pig ileum and their antinociceptive activity was determined in vivo in chemically induced writhing models (peripheral activity) and in the hot-plate test (central activity), in rodents. That the analgesic effects were predominantly mediated in the periphery was demonstrated by antagonism of antinociception by the peripheral opioid antagonist N-methylnalorphine and by comparison of the activities in the writhing and hot-plate tests. As a class, the tetrapeptides were more potent than the tripeptides; N alpha-amidination generally increased activity. A number of compounds exhibited very potent opioid activity and had the desired pharmacological profile, indicating a high degree of peripheral selectivity.
• HANSEN, DONALD W. (JR);PILIPAUSKAS, DANIEL R.;CLARE, MICHAEL
  作者：HANSEN, DONALD W. (JR)、PILIPAUSKAS, DANIEL R.、CLARE, MICHAEL

  DOI：——

  日期：——
• HARDY, GEORGE W.;LOWE, LAWRENCE A.;MILLS, GAIL;PANG, YIH SANG;SIMPKIN, DE+, J. MED. CHEM., 32,(1989) N, C. 1108-1118
  作者：HARDY, GEORGE W.、LOWE, LAWRENCE A.、MILLS, GAIL、PANG, YIH SANG、SIMPKIN, DE+

  DOI：——

  日期：——